Estudo de fase I da vacina anticâncer HASUMI

• Ano de defesa: 2004
• Autor(a) principal: Leite, Ismênia Osório
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Imunoterapia ativa; Imunoterapia; Vacinas
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/2417

The Hasumi vaccine (VH) is an imune-stimulant mode by two preparations obtained from distinctive forms, it is an assisting in a pool of tumours antigens. The assisting is taken off from calf splens and the antigen, from different forms of tumor. The VH is a sterile uncoloured liquid, conditioned in 0,5mL glass ampoules, separately. The present research aimed to evaluate, throughout a Phase I study, the security of VH, as well as the comprehension of its action mechanism. The clinical experiment was conducted in 24 healthy volunteers in wich the VH was given subcutaneously every 5 days during 2 months, accomplishing an amount in wich the two first ones were given in the hospital. Before the first administration, all the voluteers did the Prick test, to evaluate the possibility of reacting to hipersensibility. After that they were submit to clinical and laboratorial evaluation (hemogram, biochemical, urine extract and parasitological excrements exams, sorology to B and C hepatitis, HIV, FAN, reumatoidic factor, C3, CD3, CD4, CD8, IgA, IgG, IgE, IgM, PSA, CEA, AFP and HCG-beta). The planning of the experiment also had the repetition of such exams after the 3th, 6th and the 12th doses, as well as in the after-study 30 days after the last dose. By hte and of the study, significant adverse events were not observed. Therefore, in the last dose and within the stabilished treatment period of this experiment, the VH was shown to be safe and with no toxity.